Funding will support commercialization in the USA and Europe as well as continued development of MAGENTIQ COLO’s advanced AI capabilities.
MAGENTIQ EYE LTD., a leading innovator in AI-powered gastroenterology decision-support software, today announced the successful completion of its Series A funding round.
MAGENTIQ EYE’s FDA- and CE-approved software, MAGENTIQ-COLO™, enhances polyp detection and analysis capabilities during colonoscopies, significantly improving adenoma detection rates. MAGENTIQ-COLO also offers real-time insights, and its CE-approved version includes polyp-size category and type estimation, and advanced AI-generated reports.
The round was led by aMoon, Israel’s largest HealthTech dedicated investment fund, joined by internal investors Norgine Ventures BV (Netherlands), Nina Capital (EU & USA) and Namarel Ventures SL (Spain), Nova Capital (Italy), and private investors Sake Bosch and Roon Doornink (USA). In conjunction with aMoon’s investment, partner Roy Wiesner will join the board of directors of MAGENTIQ EYE, bringing strategic insight, global perspective, and deep experience in building successful health tech companies.
“This investment round marks a major milestone for MAGENTIQ EYE. We are thrilled to welcome aMoon and Roy Wiesner to our journey,” said Dror Zur, Ph.D., founder and CEO of MAGENTIQ EYE. “With aMoon’s support, we will accelerate innovation and market access, meeting the growing demand reflected in our robust pipeline of trial and purchase requests across the U.S. and Europe, and bring our advanced diagnostic tools to more physicians and patients around the world.”
“We are proud to partner with MAGENTIQ EYE, a company leading the charge in AI-powered colonoscopy,” said Wiesner. “MAGENTIQ’s solution stands out as the most accurate in the market, with the broadest set of features, cost-effective scalability, and platform flexibility across GI and laparoscopic applications. We’re also encouraged by the strong early commercial traction and the growing interest from major strategic players looking to collaborate. This investment reflects aMoon’s commitment to backing transformative health tech solutions that can dramatically improve patient outcomes worldwide.”
The company is in clinical trials for diagnostic tools targeting specialized diseases in the lower and upper gastrointestinal tract, such as ulcerative colitis, early dysplasia in Barrett’s esophagus, and gastric intestinal metaplasia, and is developing automated quality indicators for GI procedures. Proceeds from the funding round will support the continued development and expansion of these capabilities, in addition to driving commercial growth in the USA, Europe and globally through direct sales and MAGENTIQ EYE’s existing and new partnerships with industry leaders.
Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!